Bristol-Myers Squibb files melanoma drug ipilimumab BLA; gets FDA priority review

19 August 2010

The US Food and Drug Administration has accepted, for filing and review, drug major Bristol-Myers Squibb's (NYSE: BMY) Biologics License Application for ipilimumab for the treatment of adult patients with advanced melanoma who have been previously treated.

The company also announced that the application has been granted a priority review designation by the FDA, meaning a six-month target for completing the assessment, and an action date of December 25. Despite what is positive news for the company, its stock dipped 0.7% to $26.40 in afternoon trading yesterday.

Ipilimumab was acquired by B-MS along with its $2.4 billion takeover of fellow USA-based Medarex in the fall of 2009, aimed at expanding the firm's range of biological drugs and ahead of the patent expiry of the blockbuster blood thinner Plavix (clopidogrel), co-marketed with originator France's Sanofi-Aventis.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical